The Clinical Role of Inflammatory Chemokine RANTES (CCL5) in a Sample of COVID-19 Baghdad Province Patients
DOI:
https://doi.org/10.31351/vol33iss(4SI)pp304-311Keywords:
Keywords: CCL5, Chemokine, COVID-19, RANTES, Sandwich ELISAAbstract
COVID-19 disease is a clinical syndrome caused by an envelope RNA virus, called SARS-COV-2., which causes infection with wildly clinical pictures. Through COVID-19 infection several components of humoral and cellular immune response have an important role in the progression of the infection. Chemokines are one of the inflammatory mediators that play an essential role in the immune pathogenesis of COVID-19. It is secreted by respiratory virus-infected cells in the upper respiratory tract, causing stimulation and recruitment of inflammatory cells such as neutrophils, NK, eosinophils, and macrophages from the bloodstream to the site of the infection. This study strives to determine the impact role of inflammatory mediator chemokine RANTES (CCL5) in COVID-19 Iraq patients. Blood samples collected from 180 individuals were enrolled in this study, 120 of them were patients infected with COVID-19 and verified by reverse transcriptase polymerase chain reaction (RT-PCR). The patients were categorized into two groups based on the severity of the disease, the severe group included 60 patients and the mild/moderate group included 60 patients also. Furthermore, 60 healthy individuals who were confirmed to be COVID-19-negative were enrolled in this study as a control group. The quantitative detection of CCL5 in human serum was done by the CCL5 Enzyme Linked Immune Sorbent Assay kit based on the principle of sandwich ELISA. This study showed that there were interesting highly significant differences (p<0.001) in the median serum level of CCL5 between all groups that participated in this study and there was a significant increase in the median level of CCL5 in control and mild-moderate groups versus severe patients’ group (66.66 pg/ml, and 54.04 pg/ml vs. 38.41 pg/ml respectively). According to the results of this study, the low level of CCL5 associated with COVID-19 severity infection could be used as a predictor marker for severity while the elevated level of CCL5 in control and mild-moderate suggested the elevated level of this chemokine is likely to be associated with the resolution of inflammation and recovery.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Hu B, Guo H and Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021 Mar;19(3):141-154. doi: 10.1038/s41579-020-00459-7. Epub 2020 Oct 6. Erratum in: Nat Rev Microbiol. 2022 May;20(5):315. PMID: 33024307; PMCID: PMC7537588
Li X, Geng M and Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020 Apr;10(2):102-108. doi: 10.1016/j.jpha.2020.03.001. Epub 2020 Mar 5. PMID: 32282863; PMCID: PMC 710 4082.
Gallo O, Locatello LG and Mazzoni A, et al. The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. Mucosal Immunol. 2021 Mar;14(2):305-316. doi: 10.1038/s41385-020-00359-2. Epub 2020 Nov 26; PMID: 33244161; PMCID: PMC7690066.
Mick E, Kamm J and Pisco AO, et al. Upper airway gene expression reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses. Nat Commun. 2020 Nov 17;11 (1):5854. doi: 10.1038/s41467-020-19587-y. PMID: 33203890; PMCID: PMC7673985.
Ng DL, Granados AC and Santos YA, et al. A diagnostic host response biosignature for COVID-19 from RNA profiling of nasal swabs and blood. Sci Adv. 2021 Feb 3;7(6):eabe5984. doi: 10.1126/sciadv.abe5984. PMID: 33536218; PMCID: PMC7857687.
Ziegler CGK, Miao VN and Owings AH, et al. Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19. Cell. 2021 Sep 2;184(18):4713-4733.e22. doi: 10.1016/j.cell.2021.07.023. Epub 2021 Jul 23. PMID: 34352228; PMCID: PMC8299217.
Blanco-Melo D, Nilsson-Payant BE and Liu WC, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020 May 28;181(5):1036-1045.e9. doi: 10.1016/j.cell.2020.04.026. Epub 2020 May 15. PMID: 32416070; PMCID: PMC7227586.
Nuriev R, Johansson C. Chemokine regulation of inflammation during respiratory syncytial virus infection. F1000Res. 2019 Oct 31;8:F1000 Faculty Rev-1837. doi: 10.12688/f1000research.20061.1. PMID: 317 23414; PMCID: PMC6823903.
Konno S, Grindle KA and Lee WM, et al. Interferon-gamma enhances rhinovirus-induced RANTES secretion by airway epithelial cells. Am J Respir Cell Mol Biol. 2002 May;26(5):594-601. doi: 10.1165/ ajrcmb. 26. 5.4438. PMID: 11970912.
Griffith JW, Sokol CL and Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32:659-702. doi: 10.1146/annurev-immunol-032713-120145. PMID : 24655300.
Zhao Y, Qin L and Zhang P, et al. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight. 2020 Jul 9;5(13):e139834. doi: 10.1172/ jci.insight. 139834. PMID: 32501293; PMCID: PMC 7406242.
Ibtehal MS and Noor F. Ahmad. Epidemiology and Clinical Characteristics of COVID-19 patients in Al-Shaikh Zayed Hospital in Baghdad in 2020. Iraqi New Medical Journal. number 16 volume 8, July 2022.
Hussein HA. Correlation of CCL2, CCL5 and CXCL10 Chemokines with Disease Severity among Patients with COVID-19 Infection. MSC thesis ,University of Karbala Collage of Medicine. 2021
Garg A, Ghoshal U, Patel SS, Singh DV, Arya AK, Vasanth S, Pandey A, Srivastava N. Evaluation of seven commercial RT‐PCR kits for COVID‐19 testing in pooled clinical specimens. Journal of medical virology. 2021 Apr;93(4):2281-6.
Philip KE, Bennett B, Fuller S, Lonergan B, McFadyen C, Burns J, Tidswell R, Vlachou A. Working accuracy of pulse oximetry in COVID-19 patients stepping down from intensive care: a clinical evaluation. BMJ Open Respiratory Research. 2020 Dec 1;7(1): e000778
Shao LN, Zhou SH, Wang N, Zhang ST, Liu M. Association between the genetic polymorphisms of CCL2, CCL5, CCL8, CCR2, and CCR5 with chronic hepatitis C virus infection in the Chinese han population. Immunological Investigations. 2022 Jul 4;51(5):1182-97.
Al-Hatemy MD , Mohsin M I and Al-Roubaey D. The correlation between Interleukin-6 and D-dimer, Serum ferritin, CRP in COVID-19 patients in Al-Najaf province. Kufa Journal for Nursing Sciences.2022.
Saja Ibrahim Jassim, Sawsan M. Jabbar AL-Hasnawi and Dhiaa H. Jawad Al-khayat , Decreased serum levels of chemokine receptors 1 & 5 in sever-critical Iraqi COVID-19 patients. Biochem. Cell. Arch.2022 22, 2545-2552 .DocID: https:// connectjournals .com/ 038 96. 2022.22.2545.
Statsenko Y, Al Zahmi F and Habuza T, et al. Impact of Age and Sex on COVID-19 Severity Assessed From Radiologic and Clinical Findings. Front Cell Infect Microbiol. 2022 Feb 25; 11:777070. doi: 10.3389/ fcimb. 2021 .777070. PMID: 35282595; PMCID: PMC 891 3498.
Du RH, Liang LR and Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020 May 7;55(5):2000524. doi: 10.1183/ 1399 3003.00524-2020. Erratum in: Eur Respir J. 2020 Sep 24;56(3): PMID: 32269088; PMCID: PMC7144257.
Lauc G, Sinclair D. Biomarkers of biological age as predictors of COVID-19 disease severity. Aging (Albany NY). 2020 Apr 8;12(8):6490-6491. doi: 10.18632 /aging. 103052. Epub 2020 Apr 8. PMID: 32268300; PMCID: PMC7202497.
Liu NN, Tan JC and Li J, et al. COVID-19 Pandemic: Experiences in China and Implications for its Prevention and Treatment Worldwide. Curr Cancer Drug Targets. 2020; 20(6):410-416. doi: 10.2174/ 1568009 62066 6200414151419. PMID: 32286947.
Montalvo Villalba MC, Valdés Ramírez O and Muné Jiménez M, et al . Interferon gamma, TGF-β1 and RANTES expression in upper airway samples from SARS-CoV-2 infected patients. Clin Immunol. 2020 Nov; 220:108576. doi: 10.1016/j.clim.2020.108576. Epub 2020, Aug 29. PMID: 32866645; PMCID: PMC7455570.
Liao M, Liu Yand Yuan J, et al . Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020, Jun;26(6):842-844. doi: 10.1038/s41591-020-0901-9. Epub 2020 May 12. PMID: 32398875.
Patterson BK, Seethamraju H and Dhody K, et al . CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. Int J Infect Dis. 2021; Feb;103:25-32. doi: 10.1016/j.ijid.2020.10.101. Epub 2020 Nov 10. PMID: 33186704; PMCID: PMC7654230.
Li S, Jiang L and Li X, et al . Clinical and pathological investigation of patients with severe COVID-19. JCI Insight. 2020; Jun 18;5(12):e138070. doi: 10.1172/ jci.insight. 138070. PMID: 32427582; PMCID: PMC7406259.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Pharmaceutical Sciences

This work is licensed under a Creative Commons Attribution 4.0 International License.